VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Stock Comparison
EssilorLuxottica vs Novo Nordisk A/S
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
EssilorLuxottica
EL · Euronext Paris
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into EssilorLuxottica's moat claims, evidence, and risks.
View EL analysisNovo Nordisk A/S
NOVOB · Nasdaq Copenhagen
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Novo Nordisk A/S's moat claims, evidence, and risks.
View NOVOB analysisComparison highlights
- Moat score gap: Novo Nordisk A/S leads (85 / 100 vs 69 / 100 for EssilorLuxottica).
- Segment focus: EssilorLuxottica has 2 segments (52.7% in Direct to Consumer); Novo Nordisk A/S has 3 segments (71.1% in Diabetes care).
- Primary market structure: Competitive vs Oligopoly. Pricing power: Moderate vs Moderate.
- Moat breadth: EssilorLuxottica has 5 moat types across 3 domains; Novo Nordisk A/S has 5 across 3.
Primary market context
EssilorLuxottica
Direct to Consumer
Optical retail and e-commerce (prescription eyewear and sunglasses)
Global
Consumers (end-users)
Omnichannel retailer + vertically integrated manufacturer/brand owner
52.7%
Novo Nordisk A/S
Diabetes care
Diabetes pharmaceuticals (GLP-1 for type 2 diabetes, insulin, and related therapies)
Global
Payers/providers and patients (via wholesalers/pharmacies/hospitals)
Originator pharma (R&D, regulatory, manufacturing, commercialization)
71.1%
Side-by-side metrics
Moat coverage
Shared moat types
EssilorLuxottica strengths
Novo Nordisk A/S strengths
Segment mix
EssilorLuxottica segments
Full profile >Professional Solutions
Oligopoly
Direct to Consumer
Competitive
Novo Nordisk A/S segments
Full profile >Diabetes care
Oligopoly
Obesity care
Duopoly
Rare disease
Oligopoly
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listLooking for expansion-stage stocks?
Proven models entering the expansion stage with unit economics that work.
View expansion-stage stocksCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.